Tag

Radiopharmaceuticals

All articles tagged with #radiopharmaceuticals

biotech29 days ago•0 min saved

Telix Acquires ITM Isotope in $1.65B Deal to Challenge Novartis in Radiopharma

Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich for $1.65 billion upfront, with potential additional payments of up to $700 million. The deal aims to create a major competitor to Novartis in the radiopharmaceutical market by combining Telix’s pipeline with ITM’s manufacturing network and lead candidate ITM-11. Although the FDA recently rejected ITM-11 over manufacturing issues, analysts remain optimistic about the combined entity’s growth potential.

via Fierce Biotech|

#biotech #itm-11 #itm-isotope-technologies

biotechnology29 days ago

Telix Acquires ITM Isotope for $1.65B to Challenge Novartis in Radiopharma

Telix Pharmaceuticals is acquiring ITM Isotope Technologies in a deal valued at at least $1.65 billion, with potential additional payments reaching $2.35 billion. The merger follows a surprise FDA rejection of ITM’s lead drug, ITM-11, due to manufacturing issues. The combined entity aims to vertically integrate radiopharmaceutical supply chains and challenge Novartis’s dominance in the field.

via STAT|

#biotechnology #cancer-therapy #fda-regulation

biotech2 months ago•2 min saved

FDA Rejects ITM-11 Radiopharmaceutical, Stalling Rival to Novartis Therapy

The FDA rejected ITM-11, ITM Isotope Technologies Munich’s radiopharmaceutical for gastroenteropancreatic neuroendocrine tumors, due to manufacturing issues, halting a potential rival to Novartis’ therapy; early ITM data suggested ITM-11 could extend progression-free survival (23.9 months vs 14.1 months with everolimus).

via STAT|

#biotech #fda #gep-nets

business6 months ago•3 min saved

Regeneron launches radiopharma push with Telix in a potential $2.1B collaboration

Regeneron pays Telix $40 million upfront to co-develop four radiopharmaceutical programs for solid tumors, with an option to add four more. If milestones are met, Telix could earn up to $2.1 billion in biobucks, or opt for milestone-based payments under a cost-sharing model, with shared global commercialization and potential co-promotion. Regeneron will select targets from its antibody portfolio and may pair these agents with Libtayo; the deal also covers diagnostics, with Telix leading commercialization. The collaboration follows Telix’s recent radiopharma expansion and comes amid regulatory headwinds for Telix’s imaging assets.

via Fierce Biotech|

#business #oncology #partnerships

biotechnology1 year ago•1 min saved

Radiopharmaceutical Growth Stalled by Talent Shortage

The rise of radiopharmaceuticals, a new cancer treatment that targets cancer cells with radioactive isotopes, is facing a significant talent shortage. This innovative approach has attracted numerous biotech startups and substantial investments, with several companies being acquired for over $1 billion. However, the industry's growth is threatened by a lack of skilled professionals needed to develop and implement these therapies.

via STAT|

#biotech-startups #biotechnology #cancer-treatment

healthcare2 years ago•0 min saved

Radiopharmaceuticals Revolutionize Cancer Treatment

Ken Song, former CEO of a small biotech, initially avoided oncology due to its crowded nature. However, after receiving inquiries from investors about the possibility of developing more effective and widely applicable cancer treatments using radiopharmaceuticals, which deliver targeted radiation to cancer cells, he became interested in the field.

via STAT|

#biotech #cancer-treatment #healthcare